We provide the techniques and expertise to produce, archive and distribute genetically altered animals and stem cell lines.
Genetically altered models provide a powerful tool for understanding the role of genes and their contribution to health and disease. The ability to introduce specific mutations into the genome allows models of human disease to be generated, providing insights into the cellular processes underlying the disease and serving as a key resource to test and optimize new therapies and diagnostic tools.
We specialize in the use of gene targeting and CRISPR technologies for efficient gene editing and genome modification, both directly in embryos and in stem cells. For overexpression, we have solutions for site-specific insertion of transgenes and all manipulations can be made conditionally, limiting the genetic manipulation to specific tissue, cell types or timepoints.
Our group helps distribute and cryopreserve existing genetically altered animals and stem cells, using key reproductive technologies to assist Crick groups with the management of their colonies.
Technology development within the group is focused on maximizing the efficiency and accuracy of the genetic alteration, improving the quality and speed of production, and importantly reducing the animal cost of biomedical research.
The group is led by Ben Davies and is supported by Katharine Mankelow who heads the embryology and gene delivery team and Graham Duddy who heads the molecular and stem cell biology team.